Russian medicines to win world’s market
Russian and international pharmaceutical companies will cooperate in creating unique medicines on the basis of cell and gene technologies. The Russian company “ROSNANO” has supported the project “SinBio”, which unites UK, German and Russian scientists.
The aim of the project is to come up with 9 new medicines for treating diabetes, Alzheimer disease, renal disease and other grave conditions.
“A company which works out nanotechnologies cannot orient itself on the market of only one country,” Artur Isaev, the Director General of the Russian Institute of stem cells says:
“An important thing about this project is that it is linked with international cooperation. This cooperation allows to unite the world’s greatest minds in this sphere in one project. We are planning to release medicines of a totally new generation.”
The Institute of stem cells works out its own original medicines on the basis of cell and gene technologies. Now, the UK “Lipoxen” and the German “SymbioTec” companies will be the institute’s partners. To produce the new medicines, two plants will be built – in Moscow and in St. Petersburg. At present, the project’s participants are testing these medicines in laboratories.
For “ROSNANO”, this project means an opportunity to present its medicines to the world market. The Russian company invests 40% of the money into this project.
“By 2015, “SinBio” plans to sell tens of millions dollars worth of medicines,” Artur Isaev says:
“The realization of this project is an example of innovative policy in Russian pharmacological industry,” Mr. Isaev says.
The development of medical and biological technologies is one of the five main directions in modernizing the Russian economy, outlined by President Medvedev.